Androgen deprivation therapy improves survival of patients with prostate cancer and leads to hypogonadal state. Gonadal hormones are essential for skeletal integrity and hypogonadism constitutes a major risk factor for osteoporosis. To examine the bone loss secondary to androgen deprivation therapy, we reviewed the bone mineral density (BMD) studies of 152 patients with prostate cancer with mean duration of androgen deprivation therapy of 58 months. Among them 55 subjects had follow-up BMD measurement at 12-15 months with 39 of them on antiresorptive therapy. Osteoporosis was noted at least at one site in 92 (60.5%), among which 74 (48.7%) had changes at hip with the more prominent changes at ward's triangle, 18 (11.8%) at other sites. Osteopenia was present in 37 (24%) and only 17 (11%) were normal. The duration of antiandrogen therapy did not correlate with the degree of bone loss. Significant in improvement in the BMD is noted at 12-15month followup on antiresorptive therapy. We conclude that men treated with androgen deprivation therapy are at risk for bone loss and should have BMD measured at the time of initiation of androgen deprivation therapy and periodically.
Introduction
Prostate cancer is the most commonly diagnosed cancer in United States and the second leading cause of cancer deaths among American men. Carcinoma of the prostate is the most common tumor in men in the United States, with 232 090 with new cases and 30 350 deaths expected in 2005. 1, 2 In a recent review of the controversies surrounding the androgen deprivation therapy for prostate cancer, Patterson discussed at length all the available modalities of therapy. 3 Medical castration may be obtained with estrogen agonists, LHRH agonists and LHRH antagonists. When compared to 5 mg of DES, LHRH analogs have a more favorable cardiovascular safety profile with a reduced risk of deep vein thrombosis and congestive heart failure. 4, 5 Two preparations of LHRH agonists are commercially available in the United States: leuprolide acetate (Lupron) and goserelin acetate (Zoladex). When LHRH analogs are administered in nonpulsatile fashion or intermittently they act like LHRH antagonists and lead to hypogonadism. Androgen deprivation therapy with the LHRH analogs or by surgical castration results in greater than 97% decrease in serum testosterone. Estrogen, which is the normal metabolite of testosterone, diminishes correspondingly and approaches unmeasurable levels in men on androgen deprivation treatment.
Gonadal hormones are essential for skeletal integrity and hypogonadism constitutes a major risk factor for osteoporosis. Although precise estimates of its incidence, degree of severity and cost are not completely elucidated, osteoporosis is an important and debilitating side effect of androgen deprivation therapy. If left undetected or untreated, the risk for osteoporosis rises. Osteoporosis increases increase fracture risk, especially at the hips. Osteoporosis is a major cause of morbidity and mortality in both adult women and men due to an increased risk of fractures. Seeman et al. 6 reported that 30% of the 1.7 million hip fractures worldwide occurred in men. Beyond changes in bone density, androgen deprivation does affect fracture risk. A significant increase in osteoporotic fracture risk is reported following bilateral orchiectomy. 7 The increased fracture risk seen with orchiectomy was independent of smoking status, obesity, age and degree of testicular atrophy. It is reported that there is a significant correlation between the duration of androgen suppression and risk of skeletal fractures 8 with an odds ratio of 4.97 for all fractures and 5.4 for hip fractures. Hatano et al. 9 noted that the bone density was significantly lower in the patients with a fracture than in those without.
Bisphosphonates are widely used in the treatment of postmenopausal osteoporosis. Bisphosphonates reduce excessive bone turnover while preserving bone structure and mineralization in patients with other tumor types. Similar benefit in men with osteoporosis was shown in a randomized controlled study with idiopathic osteoporosis; however, men with osteoporosis due to secondary causes including androgen deprivation therapy were excluded 10 in a randomized controlled trial of men. The object of our study is to evaluate the bone loss among subjects with prostate cancer on androgen deprivation therapy and assess the benefit from the antiresorptive therapy in these subjects.
Materials and methods

Subjects and methods
We reviewed the bone density results and medical records of 152 subjects with a diagnosis of prostate adenocarcinoma, on androgen deprivation therapy with LHRH agonists alone or LHRH agonists with antiandrogens. All these men with prostate cancer had a tissue diagnosis of adenocarcinoma on a biopsy of the prostate and had been referred for measurements of bone mineral density (BMD) at our VA Medical center. Labs were drawn to confirm androgen deprivation. None of the men with prostate cancer received prior chemotherapy. Bone scans were negative for bone metastasis. The data abstracted included patient's age, diagnosis of prostate cancer and duration of androgen deprivation therapy. The exclusion criteria included those subjects with chronic and/or current steroid use, a history of abnormal thyroid function, vitamin D deficiency or chronic renal insufficiency or those with primary hyperparathyroidism.
Bone mineral density. BMD was measured at the lumbar spine (L1-L4) and proximal femur (hip) on both sides using dual energy absorptiometry (DXA) on Hologic, 2000 (Hologic, Inc., Bedford, MA, USA). All measurements were obtained and analyzed using standard protocols provided by the manufacturer. The BMD at each site was compared to the matched control values of the data of Third National Health and Nutrition Examination survey (NHANES III, 1988-1991) phase I.
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Hologic 2000 automatically calculates the t-scores (standard deviation relative to young adult age 20-40 years) for each measurement at each site from manufacturers' reference populations. The t-scores with the greatest decrease in BMD at any site (spine or either hip) are used to classify the BMD of the subjects as normal (t-scores -1 or greater), osteopenia (t-scores between À1.0 and oÀ2.5) and osteoporosis (t4À2.5).
Biochemical measurements. Markers of bone turnover were determined at baseline, 6, and 12 months. Urinary N-telopeptide concentrations were assayed from a 2-h urine collection using an enzyme-linked immunoabsorbent assay (Ostex, Seattle, WA, USA). Concentrations of bone-specific alkaline phosphatase and serum osteocalcin assayed using RIA (Metra Biosystem, Mountain View, CA, USA).
Statistical analysis
Results are expressed as mean7s.e.m. The two groups were compared for their effects on bone mass measurements. Analysis of variance for repeated measures was used to analyze differences within a group, and the unpaired Student's t-test was used to analyze changes at each time point between groups. Paired t-test used to compare the changes in BMD on antiresorbants compared to those of not on therapy. A P-value of p0.05 was considered significant difference.
Precision
The precision of the lumbar spine was 0.008 g/cm 2 (coefficient of variation (CV)% ¼ 1.0%). The precision of the total hip was 0.007 g/cm 2 (CV% ¼ 0.87%). The precision of the manufacturer's spine phantom was 0.0017 g/cm 2 (CV% ¼ 0.17%), the criteria recommended by US Preventive Services Task Force, 2002 12 is accepted currently.
Results
Demographic characteristics of the 152 subjects on androgen deprivation therapy are shown in Table 1 .
Results of BMD
Results of bone mineral densities of 152 patients with history of prostate cancer on LHRH-agonist therapy were reviewed after excluding those who have associated primary hyperparathyroidism or chronic renal insufficiency or liver disease or those on glucocorticoid therapy. One patient had wrist evaluation only in view of the weight limits of bone densitometer. Osteoporosis was noted in 92 (60.5%), among which 74 (48.7%) had changes at one hip alone with prominent changes at the Ward's triangle (11.8%) or other sites. Osteopenia was present in 37 (24%) and only 17 (11%) were normal ( Table 2) . In all, 55 subjects had a follow-up dexa at 12-15months. Among them 39 were on antiresorptive agents (either bisphosphonate or calcitonin) and the remaining 16 subjects were not on any antiresorptive agents. There was a significant interval change in both groups compared to the baseline as shown in Table 3 . On follow-up at 12-15 months there is a significant loss of BMD in those who are not antiresorptive therapy, whereas there is a statistically significant improvement in BMD in the group on antiresorptive therapy.
Discussion
Hypogonadism is the major cause of osteoporosis in women as well as men. The use of androgen deprivation therapy including leutinizing hormone-releasing hormone (LHRH) agonists is the favored treatment in the management of prostate cancer. As the natural history of prostate cancer has changed, the issue of treatmentrelated skeletal complications has become increasingly important. Our results demonstrate four major findings. First, significant bone loss is associated with androgen deprivation therapy in men with prostate cancer. Second, the severity of changes does not correlate with the duration of androgen deprivation therapy. Third, the total hip is the skeletal site most affected. Fourth, there is a marked improvement with the use of antiresorbants.
In women, the rate of bone loss is maximum at the spine more than the other sites in the early postmenopausal years. 13, 14 Pouilles et al. 14 concluded that spontaneous vertebral and femoral bone loss exhibit a great variability within the first postmenopausal years and that only a small minority of women sustain a fast rate of bone loss over several years. The rate of loss is reported to be between 1.46 and 1.82% per year but can be as high as 5%. In healthy normal men, the rate of loss cortical bone mass is 0.5-1% per year. 15 In men on GnRH agonist therapy, significant bone loss is reported more so in the initial 12 months of continuous ADT with the rate of bone loss ranging from 2 to 8% in the lumbar spine and 1.8 to 6.5% in the femoral neck. [16] [17] [18] We noted that the patients on androgen deprivation therapy for prostate cancer have marked decrease in BMD (Table 2) . Our results suggest that the BMD is significantly lower at almost all the measured sites with marked changes are noted at the hip. These results are similar to the results reported suggesting the total hip and distal radius as the preferred sites for monitoring bone loss in subjects with prostate cancer on androgen deprivation therapy. 19 Along with low bone mass, patients do have increased bone turnover markers. Changes in the BMD did not correlate with the duration of therapy. In addition, the severity of BMD changes could not be explained by the androgen deprivation therapy alone. There is enough data to suggest that androgen deprivation therapy is associated with increased fracture risk in patients with prostate cancer with as much as 5% fracture incidence. 20, 9, 8, 21 We noted marked changes at the hip. Total hip BMD was the strongest predictor of fracture risk in women where as wrist BMD was best in men. 22 The predictors of femoral neck fractures are neck/shaft angle (NSA), medial calcar femoral cortex width (CFC), the trochanter (TRBMD), and Ward's triangle (WABMD). 23 On followup at 12-15 months, we noted a significant interval change compared to that of baseline (Table 3) . At 12-15 months follow-up significant loss of BMD is noted in those who are not antiresorptive therapy, whereas significant improvement in BMD is noted in the group on antiresorptive therapy. Bisphosphonates are assuming a prominent ancillary role in prostate cancer therapy through their ability to prevent skeletal morbidity. Their potential to interfere with the formation of osseous tumor deposits has lead to investigations into the capacity of these drugs to prevent bone metastasis. Van Poznak discussed the role of bisphosphonates in patients with breast cancer and concluded that bisphosphonates are the treatment of choice for hypercalcemia of malignancy and bisphosphonates reduce the risk of pathologic fractures, spinal cord compromise, the need for radiation or surgery to bone, and bone pain. 24 They may have similar role in the management of prostate cancer management. The severity of BMD changes cannot be explained by the androgen deprivation therapy alone. Tumors themselves will cause direct osteoclast activity leading to bony complications of the disease. We believe further studies are warranted to prove the hypothesis. Researchers are studying the effects of LHRH agonist therapy on osteoporosis and 
Summary and conclusions
Osteoporosis is a risk associated with androgen deprivation therapy. Bisphosphonates reduce bone loss in men with prostate cancer who are being treated with androgen deprivation therapy and are well tolerated. Physicians need to be aware of the potential for osteoporosis and should have the BMD and bone turn over markers measured at base line and follow-up at reasonable intervals. Those patients with osteoporosis should be treated with antiresorptive agents. Even those subjects with osteopenia should be considered for preventive therapy with antiresorptive agents. General lifestyle and diet modifications as well as calcium and vitamin D supplementation should be initiated at the start of androgen deprivation therapy to minimize bone loss.
